effect of synbiotics in elderly diabetic patients

A Gut-Targeted Synbiotics with Vildagliptin Metformin in Elderly Type 2 Diabetes: Impact on Glycemic Control, Oxidative Stress, Inflammatory Respnse and Insulin Sensitivity An Open-Label Randomized Controlled Trial - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/07/090888

Enrollment

210

Registered

2025-07-14

Start date

Unknown

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Synbiotics: Group 2 will be prescribed Synbiotics, Vildagliptin 50mg and Metformin 500mg in fixed dose once a day after food in the morning Control Intervention1: Vildagliptin 50mg an

Eligibility

Inclusion criteria

Inclusion criteria: Age group- 60- 85 years Both the genders Diagnosed with type 2 diabetes mellitus patients HbA1c level between 7 to 8% Diabetes with or without hypertension Diabetes with or without dyslipidaemia

Exclusion criteria

Exclusion criteria: Diabetes with renal failure Diabetes with liver failure Age below 60 years

Design outcomes

Primary

Measure	Time frame
Reduction of Serum Glucose level and HbA1C levelTimepoint: Reduction of Serum Glucose level and HbA1C level	—

Secondary

Measure	Time frame
Reduction of Inflammation and Oxidative Stress and Insulin sensitivityTimepoint: 3 months	—

Countries

India

Contacts

Public ContactKala P

bharathiclinic2019@gmail.com9962393389

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026